CN1942583A - Hpv58l1在酵母中的最优化表达 - Google Patents
Hpv58l1在酵母中的最优化表达 Download PDFInfo
- Publication number
- CN1942583A CN1942583A CNA2004800332355A CN200480033235A CN1942583A CN 1942583 A CN1942583 A CN 1942583A CN A2004800332355 A CNA2004800332355 A CN A2004800332355A CN 200480033235 A CN200480033235 A CN 200480033235A CN 1942583 A CN1942583 A CN 1942583A
- Authority
- CN
- China
- Prior art keywords
- yeast
- vlps
- hpv58
- hpv
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 46
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims description 85
- 229960005486 vaccine Drugs 0.000 claims abstract description 37
- 210000005253 yeast cell Anatomy 0.000 claims abstract description 27
- 239000002245 particle Substances 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 82
- 108020004705 Codon Proteins 0.000 claims description 59
- 210000004027 cell Anatomy 0.000 claims description 48
- 239000002773 nucleotide Substances 0.000 claims description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 10
- 238000005457 optimization Methods 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 241001631646 Papillomaviridae Species 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 6
- 230000008521 reorganization Effects 0.000 claims description 6
- 241000235058 Komagataella pastoris Species 0.000 claims description 5
- 238000013467 fragmentation Methods 0.000 claims description 5
- 238000006062 fragmentation reaction Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 244000286779 Hansenula anomala Species 0.000 claims description 3
- 235000014683 Hansenula anomala Nutrition 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000057593 human F8 Human genes 0.000 claims 1
- 229940047431 recombinate Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 50
- 102000004169 proteins and genes Human genes 0.000 abstract description 20
- 108091033319 polynucleotide Proteins 0.000 abstract description 10
- 102000040430 polynucleotide Human genes 0.000 abstract description 10
- 239000002157 polynucleotide Substances 0.000 abstract description 10
- 230000003472 neutralizing effect Effects 0.000 abstract description 5
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract description 4
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 86
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 79
- 108020004414 DNA Proteins 0.000 description 41
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 41
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 30
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 28
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 23
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 23
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 108010058643 Fungal Proteins Proteins 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- 101150075239 L1 gene Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000008676 import Effects 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-M leucinate Chemical compound CC(C)CC(N)C([O-])=O ROHFNLRQFUQHCH-UHFFFAOYSA-M 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 8
- 229960002920 sorbitol Drugs 0.000 description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 201000010881 cervical cancer Diseases 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 108700005078 Synthetic Genes Proteins 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
- 229960005542 ethidium bromide Drugs 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229960002566 papillomavirus vaccine Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 2
- 101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 2
- 101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 2
- 101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 2
- 101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150094690 GAL1 gene Proteins 0.000 description 2
- 102100028501 Galanin peptides Human genes 0.000 description 2
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 2
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 241000701784 Human papillomavirus type 58 Species 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 101150027802 L2 gene Proteins 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 2
- 101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 2
- 101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 2
- 101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 2
- 101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 2
- 101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 2
- 101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 2
- 101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 2
- 101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 2
- 101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100039555 Galectin-7 Human genes 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710135729 Major capsid protein L1 Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 206010056286 Nipple neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- -1 methane amide Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 102220023258 rs387907548 Human genes 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (29)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51921103P | 2003-11-12 | 2003-11-12 | |
US60/519,211 | 2003-11-12 | ||
PCT/US2004/037372 WO2005047315A2 (en) | 2003-11-12 | 2004-11-10 | Optimized expression of hpv 58 l1 in yeast |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1942583A true CN1942583A (zh) | 2007-04-04 |
CN1942583B CN1942583B (zh) | 2010-10-27 |
Family
ID=34590374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800332355A Active CN1942583B (zh) | 2003-11-12 | 2004-11-10 | Hpv58l1在酵母中的最优化表达 |
Country Status (32)
Country | Link |
---|---|
US (2) | US7498036B2 (zh) |
EP (1) | EP1687329B8 (zh) |
JP (2) | JP4912885B2 (zh) |
KR (1) | KR101170654B1 (zh) |
CN (1) | CN1942583B (zh) |
AR (1) | AR046835A1 (zh) |
AT (1) | ATE452977T1 (zh) |
AU (1) | AU2004290032B2 (zh) |
BE (1) | BE2015C070I2 (zh) |
BR (1) | BRPI0416393B1 (zh) |
CA (1) | CA2543928C (zh) |
CY (2) | CY1113875T1 (zh) |
DE (1) | DE602004024821D1 (zh) |
DK (1) | DK1687329T3 (zh) |
ES (1) | ES2340287T3 (zh) |
FR (1) | FR15C0081I2 (zh) |
HU (1) | HUS1500064I1 (zh) |
IL (1) | IL175353A (zh) |
IS (1) | IS2741B (zh) |
LT (1) | LTC1687329I2 (zh) |
LU (1) | LU92901I2 (zh) |
MY (1) | MY139500A (zh) |
NL (1) | NL300775I1 (zh) |
NO (2) | NO340633B1 (zh) |
NZ (1) | NZ546697A (zh) |
PL (1) | PL1687329T3 (zh) |
PT (1) | PT1687329E (zh) |
RU (1) | RU2370538C2 (zh) |
SI (1) | SI1687329T1 (zh) |
TW (1) | TWI332988B (zh) |
WO (1) | WO2005047315A2 (zh) |
ZA (1) | ZA200603106B (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101644979A (zh) * | 2008-07-31 | 2010-02-10 | 苹果公司 | 位于黑障板后面的电容传感器 |
CN101835797A (zh) * | 2007-11-23 | 2010-09-15 | 上海泽润生物科技有限公司 | 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途 |
CN101857870A (zh) * | 2010-06-12 | 2010-10-13 | 上海泽润生物科技有限公司 | Hpv58 l1基因及载体、菌株和表达方法 |
CN101113417B (zh) * | 2007-06-22 | 2011-04-27 | 山东大学 | Hpv基因酵母体外翻译系统的建立 |
CN101200696B (zh) * | 2007-11-14 | 2011-07-20 | 山东大学 | 人乳头瘤病毒的酵母增殖模型及建立方法与应用 |
CN102154325A (zh) * | 2011-01-01 | 2011-08-17 | 上海生物制品研究所 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
WO2012006962A1 (zh) * | 2010-07-16 | 2012-01-19 | 厦门大学 | 截短的人乳头瘤病毒58型l1蛋白 |
CN103361280A (zh) * | 2012-03-28 | 2013-10-23 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
CN103992395A (zh) * | 2013-02-18 | 2014-08-20 | 北京康乐卫士生物技术股份有限公司 | 重组hpv-58型l1的vlp疫苗及其制备方法 |
CN104164373A (zh) * | 2013-05-17 | 2014-11-26 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生 hpv68l1 蛋白的方法 |
CN104878022A (zh) * | 2015-04-27 | 2015-09-02 | 段青姣 | 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用 |
CN110423774A (zh) * | 2013-04-26 | 2019-11-08 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 |
CN113073105A (zh) * | 2021-03-23 | 2021-07-06 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
US8206950B2 (en) * | 2003-06-09 | 2012-06-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine and method of making them |
PL1730175T3 (pl) | 2004-03-24 | 2010-09-30 | Merck Sharp & Dohme | Optymalizowana ekspresja L1 HPV 52 w drożdżach |
US20070243587A1 (en) * | 2006-04-14 | 2007-10-18 | Healthbanks Biotech Co., Ltd. | Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus |
CN101148661B (zh) * | 2006-09-18 | 2013-01-02 | 中国医学科学院基础医学研究所 | 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途 |
US7709010B2 (en) * | 2007-03-09 | 2010-05-04 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
US9428555B2 (en) | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
WO2008134935A1 (fr) | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Protéines 18 l1 de type papillomavirus humain tronqué |
WO2008145021A1 (en) * | 2007-05-29 | 2008-12-04 | Xiamen University | A truncated l1 protein of human papillomavirus 6 |
KR20090073987A (ko) * | 2007-12-31 | 2009-07-03 | 정운원 | 인간유두종바이러스 유전자형 검사를 위한 프라이머, 프로브 및 이를 포함하는 dna칩, 이의 검사 방법 및 검사 키트 |
US9623098B2 (en) * | 2008-05-26 | 2017-04-18 | Cadila Healthcare Limited | Combined measles-human papilloma vaccine |
US9376727B2 (en) | 2010-05-25 | 2016-06-28 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically truncated probes |
AU2012270418B2 (en) * | 2011-06-15 | 2015-08-13 | Posvax Co., Ltd | Method for enhancing the production yield of human papillomavirus L1 protein |
AU2013272283B2 (en) * | 2012-06-07 | 2018-02-15 | The Children's Hospital Of Philadelphia | Controlled gene expression methods |
CN104164374B (zh) * | 2013-05-17 | 2019-10-22 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv31 l1蛋白的方法 |
EP3057612B1 (en) | 2013-10-16 | 2020-05-06 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
JP2017528137A (ja) * | 2014-09-11 | 2017-09-28 | カディラ ヘルスケア リミティド | 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン |
CN106148359A (zh) * | 2015-03-30 | 2016-11-23 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒33亚型蛋白表达 |
KR102351259B1 (ko) * | 2015-12-04 | 2022-01-14 | 시아먼 유니버시티 | 58형 인유두종 바이러스 엘1 단백질의 돌연변이체 |
CR20220395A (es) | 2020-02-14 | 2022-10-27 | Merck Sharp & Dome Llc | Vacuna contra hpv |
CN113549634B (zh) * | 2021-06-07 | 2023-03-31 | 郑州大学 | 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用 |
US20230048144A1 (en) | 2021-08-06 | 2023-02-16 | Merck Sharp & Dohme Llc | Hpv vaccine |
CA3229064A1 (en) | 2021-08-19 | 2023-02-23 | Andrew Bett | Thermostable lipid nanoparticle and methods of use thereof |
CN117054647A (zh) * | 2023-07-17 | 2023-11-14 | 广东省一鼎生物技术有限公司 | 一种检测HPV IgG抗体试剂盒及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117591A0 (en) | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
US5821087A (en) | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
CA2280195A1 (en) | 1997-02-07 | 1998-08-13 | Merck & Co., Inc. | Synthetic hiv gag genes |
JP4434479B2 (ja) | 1997-07-09 | 2010-03-17 | ザ・ユニバーシティ・オブ・クイーンズランド | 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法 |
IL141130A0 (en) * | 1998-08-14 | 2002-02-10 | Merck & Co Inc | Process for purifying human papilloma virus-like particles |
JP4563582B2 (ja) | 1998-08-14 | 2010-10-13 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒトパピローマウイルスのウイルス様粒子を使用するタンパク質送達系 |
SE514982C2 (sv) * | 1999-09-30 | 2001-05-28 | Active Biotech Ab | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
JP4799789B2 (ja) * | 1999-08-25 | 2011-10-26 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子 |
US6436402B1 (en) | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
IL154009A0 (en) | 2000-07-21 | 2003-07-31 | Glaxo Group Ltd | Codon-optimized papilloma virus sequences |
AU2003219760A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
KR101080628B1 (ko) * | 2003-03-24 | 2011-11-08 | 머크 샤프 앤드 돔 코포레이션 | 효모에서 hpv 31 l1의 최적 발현 |
MY140664A (en) * | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
-
2004
- 2004-11-09 MY MYPI20044678A patent/MY139500A/en unknown
- 2004-11-10 JP JP2006539751A patent/JP4912885B2/ja active Active
- 2004-11-10 US US10/579,111 patent/US7498036B2/en active Active
- 2004-11-10 AR ARP040104141A patent/AR046835A1/es active IP Right Grant
- 2004-11-10 AT AT04810619T patent/ATE452977T1/de active
- 2004-11-10 NZ NZ546697A patent/NZ546697A/en unknown
- 2004-11-10 SI SI200431328T patent/SI1687329T1/sl unknown
- 2004-11-10 CA CA2543928A patent/CA2543928C/en active Active
- 2004-11-10 PL PL04810619T patent/PL1687329T3/pl unknown
- 2004-11-10 WO PCT/US2004/037372 patent/WO2005047315A2/en active Application Filing
- 2004-11-10 BR BRPI0416393-1A patent/BRPI0416393B1/pt active IP Right Grant
- 2004-11-10 CN CN2004800332355A patent/CN1942583B/zh active Active
- 2004-11-10 PT PT04810619T patent/PT1687329E/pt unknown
- 2004-11-10 DE DE602004024821T patent/DE602004024821D1/de active Active
- 2004-11-10 DK DK04810619.9T patent/DK1687329T3/da active
- 2004-11-10 EP EP04810619A patent/EP1687329B8/en active Active
- 2004-11-10 KR KR1020067009199A patent/KR101170654B1/ko active Protection Beyond IP Right Term
- 2004-11-10 ES ES04810619T patent/ES2340287T3/es active Active
- 2004-11-10 RU RU2006120402/13A patent/RU2370538C2/ru active
- 2004-11-10 AU AU2004290032A patent/AU2004290032B2/en active Active
- 2004-11-11 TW TW093134524A patent/TWI332988B/zh active
-
2006
- 2006-04-19 ZA ZA200603106A patent/ZA200603106B/en unknown
- 2006-04-21 IS IS8425A patent/IS2741B/is unknown
- 2006-05-01 IL IL175353A patent/IL175353A/en active IP Right Grant
- 2006-06-09 NO NO20062674A patent/NO340633B1/no active Protection Beyond IP Right Term
-
2009
- 2009-01-26 US US12/321,797 patent/US7976848B2/en active Active
-
2010
- 2010-03-19 CY CY20101100258T patent/CY1113875T1/el unknown
-
2011
- 2011-12-08 JP JP2011268598A patent/JP5616879B2/ja active Active
-
2015
- 2015-11-30 NL NL300775C patent/NL300775I1/nl unknown
- 2015-12-02 HU HUS1500064C patent/HUS1500064I1/hu unknown
- 2015-12-04 FR FR15C0081C patent/FR15C0081I2/fr active Active
- 2015-12-07 CY CY2015051C patent/CY2015051I2/el unknown
- 2015-12-08 LT LTPA2015048C patent/LTC1687329I2/lt unknown
- 2015-12-08 LU LU92901C patent/LU92901I2/xx unknown
- 2015-12-09 BE BE2015C070C patent/BE2015C070I2/nl unknown
-
2017
- 2017-11-10 NO NO2017058C patent/NO2017058I1/no unknown
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101113417B (zh) * | 2007-06-22 | 2011-04-27 | 山东大学 | Hpv基因酵母体外翻译系统的建立 |
CN101200696B (zh) * | 2007-11-14 | 2011-07-20 | 山东大学 | 人乳头瘤病毒的酵母增殖模型及建立方法与应用 |
CN101835797A (zh) * | 2007-11-23 | 2010-09-15 | 上海泽润生物科技有限公司 | 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途 |
CN101644979A (zh) * | 2008-07-31 | 2010-02-10 | 苹果公司 | 位于黑障板后面的电容传感器 |
CN101857870B (zh) * | 2010-06-12 | 2012-09-05 | 上海泽润生物科技有限公司 | Hpv58 l1基因及载体、菌株和表达方法 |
CN101857870A (zh) * | 2010-06-12 | 2010-10-13 | 上海泽润生物科技有限公司 | Hpv58 l1基因及载体、菌株和表达方法 |
US9382296B2 (en) | 2010-07-16 | 2016-07-05 | Xiamen University | Truncated L1 protein of human papillomavirus type 58 |
CN102336822A (zh) * | 2010-07-16 | 2012-02-01 | 厦门大学 | 截短的人乳头瘤病毒58型l1蛋白 |
WO2012006962A1 (zh) * | 2010-07-16 | 2012-01-19 | 厦门大学 | 截短的人乳头瘤病毒58型l1蛋白 |
CN102336822B (zh) * | 2010-07-16 | 2015-10-14 | 厦门大学 | 截短的人乳头瘤病毒58型l1蛋白 |
CN102154325A (zh) * | 2011-01-01 | 2011-08-17 | 上海生物制品研究所 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
CN103361280A (zh) * | 2012-03-28 | 2013-10-23 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
CN103361280B (zh) * | 2012-03-28 | 2018-07-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
CN103992395A (zh) * | 2013-02-18 | 2014-08-20 | 北京康乐卫士生物技术股份有限公司 | 重组hpv-58型l1的vlp疫苗及其制备方法 |
CN110423774A (zh) * | 2013-04-26 | 2019-11-08 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 |
CN104164373A (zh) * | 2013-05-17 | 2014-11-26 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生 hpv68l1 蛋白的方法 |
CN104164373B (zh) * | 2013-05-17 | 2019-04-02 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv68l1蛋白的方法 |
CN104878022A (zh) * | 2015-04-27 | 2015-09-02 | 段青姣 | 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用 |
CN113073105A (zh) * | 2021-03-23 | 2021-07-06 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1942583A (zh) | Hpv58l1在酵母中的最优化表达 | |
CN1934131A (zh) | Hpv52 l1在酵母中的优化表达 | |
CN1859923A (zh) | Hpv 45 l1在酵母中的优化表达 | |
CN1761759A (zh) | Hpv31l1在酵母中的优化表达 | |
CN1309739C (zh) | 作为载体的新的融合蛋白质 | |
CN1720060A (zh) | 人乳头瘤病毒多肽和免疫原性组合物 | |
CN1411512A (zh) | 嵌合的免疫原性组合物及其编码核酸 | |
CN1961001A (zh) | 参与病毒蛋白的免疫抑制作用的调节的多肽序列 | |
CN1170934C (zh) | 源自白斑综合征病毒的蛋白质及其应用 | |
CN1119459A (zh) | 肿瘤疫苗的制备方法 | |
CN1798844A (zh) | Sars病毒抗原的细胞表面表达载体和用该载体转化的微生物 | |
CN101054582A (zh) | A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用 | |
CN1526072A (zh) | 埃-巴二氏病毒(ebv)肿瘤相关潜伏膜蛋白的胞外结构域的鉴定方法和与之反应的抗体试剂的选择方法 | |
CN1173203A (zh) | 纯化的乳头状瘤病毒蛋白 | |
CN1259051A (zh) | 稳定化后的人乳头瘤病毒制剂 | |
CN1791675A (zh) | 表达病毒大包膜蛋白和目的蛋白融合体的病毒载体 | |
CN1255540C (zh) | 一株疫苗诱导的乙型肝炎病毒株及其应用 | |
CN1784424A (zh) | 编码人癌胚抗原的合成基因及其用途 | |
CN1656116A (zh) | 包含hpv-16病毒的突变e7蛋白的非免疫抑制免疫原性组合物或疫苗组合物 | |
CN1433430A (zh) | 肝炎病毒岗哨病毒ⅰ(svi) | |
CN1720261A (zh) | 疫苗 | |
CN1763203A (zh) | 一种基因重组人巨细胞病毒融合蛋白pp150/MDBP及其制备方法与应用 | |
CN1775802A (zh) | 人类乳头瘤病毒免疫原性多肽、其制备方法及应用 | |
CN1297312C (zh) | 一种肿瘤增殖相关生长因子的重组噬菌体疫苗及其应用 | |
CN100342013C (zh) | 密码子优化的杯状病毒衣壳蛋白的编码核苷酸序列及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SCHERING CORP (US) Free format text: FORMER OWNER: MSD CORP. Effective date: 20121025 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
CP01 | Change in the name or title of a patent holder |
Address after: New jersey, USA Patentee after: MERCK SHARP & DOHME Corp. Address before: New jersey, USA Patentee before: SCHERING Corp. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121025 Address after: New jersey, USA Patentee after: SCHERING Corp. Address before: New jersey, USA Patentee before: MERCK SHARP & DOHME Corp. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20220902 Address after: new jersey Patentee after: MERCK SHARP & DOHME B.V. Address before: new jersey Patentee before: MERCK SHARP & DOHME Corp. |
|
TR01 | Transfer of patent right |